Comparative evaluation of protective antigen produced from Bacillus anthracis & Escherichia coli

Seetharama S. Konduru, U. Tuteja, K. Bala Krishna, H. V. Batra

Research output: Contribution to journalArticle

Abstract

Background & objective: Anthrax has been reported from almost every country and India is endemic for this disease. There is considerable under reporting of the disease because of lack of microbiological facilities and diagnostic reagents. In India only conventional methods which have limitations, are being used to diagnose the disease. Hence the aim of this study was to isolate and purify protective antigen (PA) using different protocols and to use this PA for detection of anti-PA antibodies from sera samples. Methods: Protective antigen was isolated and purified from the Sterne strain of Bacillus anthracis, B. anthracis lacking pXO1 and pXO2 transformed with pYS5 (B. anthracis pYS5) and recombinant Escherichia coli transformed with pQE30 containing PA gene using hydroxyapatite (HA), Q-sepharose fast protein liquid chromatography (FPLC) and nickel-nitrilotriacetic acid (Ni-NTA) chromatographic methods, respectively. A mixture of PA and edema factor (EF) was injected subcutaneously into rabbits to test the biological activity of PA. The immunogenicity of PA was tested by inoculating the protein into rabbits along with adjuvant. Using this PA, 20 bovine sera samples (pre- and post-vaccinated) were tested by Western blotting (WB) for the presence of anti-PA antibodies. Results: The 83 kDa PA protein was obtained from all the bacteria with the yields of 13, 50 and 9.0 mg/1 from Sterne B. anthracis, B. anthracis pYS5 and recombinant Esch. coli, respectively. Formation of edematous ulcers at the site of PA+EF injection clearly confirmed the retention of biological activity of the proteins. Of the 10 post-vaccination sera tested, 9 showed clear positive by WB whereas none of the pre-vaccination sera showed the reaction. Interpretation & conclusion: The purified PA preparations obtained in the present study may possibly be utilized for detection of anti-PA antibodies in the sera of anthrax patients for timely diagnosis of the disease and, might also be tested for their efficacy and use as human anthrax vaccine.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalIndian Journal of Medical Research
Volume117
Issue numberMAR.
Publication statusPublished - 1 Mar 2003
Externally publishedYes

Fingerprint

Escherichia coli
Antigens
Bacillus anthracis
Anthrax
Serum
Bioactivity
anthrax toxin
Antibodies
India
Vaccination
Proteins
Anthrax Vaccines
Western Blotting
Rabbits
Endemic Diseases
Liquid chromatography
Bacilli
Durapatite
Liquid Chromatography
Sepharose

Keywords

  • Anti-PA antibodies
  • Bacillus anthracis
  • Biological activity
  • Immunogenicity
  • Protective antigen (PA)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Comparative evaluation of protective antigen produced from Bacillus anthracis & Escherichia coli. / Konduru, Seetharama S.; Tuteja, U.; Bala Krishna, K.; Batra, H. V.

In: Indian Journal of Medical Research, Vol. 117, No. MAR., 01.03.2003, p. 111-118.

Research output: Contribution to journalArticle

@article{b7db947374254e3fa5a9d91a28ac4865,
title = "Comparative evaluation of protective antigen produced from Bacillus anthracis & Escherichia coli",
abstract = "Background & objective: Anthrax has been reported from almost every country and India is endemic for this disease. There is considerable under reporting of the disease because of lack of microbiological facilities and diagnostic reagents. In India only conventional methods which have limitations, are being used to diagnose the disease. Hence the aim of this study was to isolate and purify protective antigen (PA) using different protocols and to use this PA for detection of anti-PA antibodies from sera samples. Methods: Protective antigen was isolated and purified from the Sterne strain of Bacillus anthracis, B. anthracis lacking pXO1 and pXO2 transformed with pYS5 (B. anthracis pYS5) and recombinant Escherichia coli transformed with pQE30 containing PA gene using hydroxyapatite (HA), Q-sepharose fast protein liquid chromatography (FPLC) and nickel-nitrilotriacetic acid (Ni-NTA) chromatographic methods, respectively. A mixture of PA and edema factor (EF) was injected subcutaneously into rabbits to test the biological activity of PA. The immunogenicity of PA was tested by inoculating the protein into rabbits along with adjuvant. Using this PA, 20 bovine sera samples (pre- and post-vaccinated) were tested by Western blotting (WB) for the presence of anti-PA antibodies. Results: The 83 kDa PA protein was obtained from all the bacteria with the yields of 13, 50 and 9.0 mg/1 from Sterne B. anthracis, B. anthracis pYS5 and recombinant Esch. coli, respectively. Formation of edematous ulcers at the site of PA+EF injection clearly confirmed the retention of biological activity of the proteins. Of the 10 post-vaccination sera tested, 9 showed clear positive by WB whereas none of the pre-vaccination sera showed the reaction. Interpretation & conclusion: The purified PA preparations obtained in the present study may possibly be utilized for detection of anti-PA antibodies in the sera of anthrax patients for timely diagnosis of the disease and, might also be tested for their efficacy and use as human anthrax vaccine.",
keywords = "Anti-PA antibodies, Bacillus anthracis, Biological activity, Immunogenicity, Protective antigen (PA)",
author = "Konduru, {Seetharama S.} and U. Tuteja and {Bala Krishna}, K. and Batra, {H. V.}",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "117",
pages = "111--118",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "MAR.",

}

TY - JOUR

T1 - Comparative evaluation of protective antigen produced from Bacillus anthracis & Escherichia coli

AU - Konduru, Seetharama S.

AU - Tuteja, U.

AU - Bala Krishna, K.

AU - Batra, H. V.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background & objective: Anthrax has been reported from almost every country and India is endemic for this disease. There is considerable under reporting of the disease because of lack of microbiological facilities and diagnostic reagents. In India only conventional methods which have limitations, are being used to diagnose the disease. Hence the aim of this study was to isolate and purify protective antigen (PA) using different protocols and to use this PA for detection of anti-PA antibodies from sera samples. Methods: Protective antigen was isolated and purified from the Sterne strain of Bacillus anthracis, B. anthracis lacking pXO1 and pXO2 transformed with pYS5 (B. anthracis pYS5) and recombinant Escherichia coli transformed with pQE30 containing PA gene using hydroxyapatite (HA), Q-sepharose fast protein liquid chromatography (FPLC) and nickel-nitrilotriacetic acid (Ni-NTA) chromatographic methods, respectively. A mixture of PA and edema factor (EF) was injected subcutaneously into rabbits to test the biological activity of PA. The immunogenicity of PA was tested by inoculating the protein into rabbits along with adjuvant. Using this PA, 20 bovine sera samples (pre- and post-vaccinated) were tested by Western blotting (WB) for the presence of anti-PA antibodies. Results: The 83 kDa PA protein was obtained from all the bacteria with the yields of 13, 50 and 9.0 mg/1 from Sterne B. anthracis, B. anthracis pYS5 and recombinant Esch. coli, respectively. Formation of edematous ulcers at the site of PA+EF injection clearly confirmed the retention of biological activity of the proteins. Of the 10 post-vaccination sera tested, 9 showed clear positive by WB whereas none of the pre-vaccination sera showed the reaction. Interpretation & conclusion: The purified PA preparations obtained in the present study may possibly be utilized for detection of anti-PA antibodies in the sera of anthrax patients for timely diagnosis of the disease and, might also be tested for their efficacy and use as human anthrax vaccine.

AB - Background & objective: Anthrax has been reported from almost every country and India is endemic for this disease. There is considerable under reporting of the disease because of lack of microbiological facilities and diagnostic reagents. In India only conventional methods which have limitations, are being used to diagnose the disease. Hence the aim of this study was to isolate and purify protective antigen (PA) using different protocols and to use this PA for detection of anti-PA antibodies from sera samples. Methods: Protective antigen was isolated and purified from the Sterne strain of Bacillus anthracis, B. anthracis lacking pXO1 and pXO2 transformed with pYS5 (B. anthracis pYS5) and recombinant Escherichia coli transformed with pQE30 containing PA gene using hydroxyapatite (HA), Q-sepharose fast protein liquid chromatography (FPLC) and nickel-nitrilotriacetic acid (Ni-NTA) chromatographic methods, respectively. A mixture of PA and edema factor (EF) was injected subcutaneously into rabbits to test the biological activity of PA. The immunogenicity of PA was tested by inoculating the protein into rabbits along with adjuvant. Using this PA, 20 bovine sera samples (pre- and post-vaccinated) were tested by Western blotting (WB) for the presence of anti-PA antibodies. Results: The 83 kDa PA protein was obtained from all the bacteria with the yields of 13, 50 and 9.0 mg/1 from Sterne B. anthracis, B. anthracis pYS5 and recombinant Esch. coli, respectively. Formation of edematous ulcers at the site of PA+EF injection clearly confirmed the retention of biological activity of the proteins. Of the 10 post-vaccination sera tested, 9 showed clear positive by WB whereas none of the pre-vaccination sera showed the reaction. Interpretation & conclusion: The purified PA preparations obtained in the present study may possibly be utilized for detection of anti-PA antibodies in the sera of anthrax patients for timely diagnosis of the disease and, might also be tested for their efficacy and use as human anthrax vaccine.

KW - Anti-PA antibodies

KW - Bacillus anthracis

KW - Biological activity

KW - Immunogenicity

KW - Protective antigen (PA)

UR - http://www.scopus.com/inward/record.url?scp=0141459415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141459415&partnerID=8YFLogxK

M3 - Article

VL - 117

SP - 111

EP - 118

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - MAR.

ER -